Advanced search×

Early activity in the ICU: beyond safety and feasibility.

Ramona O RO Hopkins

Respir Care 55(4):481-4 (2010) PMID 20406518

Version: za2963e q8zaf q8zb5 q8zc2 q8zd6 q8ze5 q8zf4 q8zg8
Buy PDF

Similar articles you may find interesting…

  1. A Phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced ha...
    Gert J Ossenkoppele, Bob Lowenberg, and Phillip M Debnam

    Br J Haematol (2013) PMID 23647373

    Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi). This first-in-human, standard 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to determine the safety, tolerability, pharmacokinetic and pharmacodynamic profile o...
    Buy PDF
  2. Liposome-Encapsulated Hemoglobin Ameliorates Ischemic Stroke in Nonhuman Primates: Longitudinal Observation.
    Akira T Kawaguchi, Munetaka Haida, and Hideo Tsukada

    Artif Organs (2013) PMID 23647614

    Liposome-encapsulated hemoglobin (LEH) is protective early after brain ischemia in rats and nonhuman primates, but it remains unclear whether the protection persists and confers any benefits beyond the acute phase of brain ischemia and reperfusion. Ten monkeys underwent middle cerebr...
    Buy PDF
  3. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: A herbal medi...
    Samantha Coulson, Amanda Rao, and Luis Vitetta

    Complement Ther Med 21(3):172-9 (2013) PMID 23642948

    The aim of the clinical trial was to evaluate the efficacy and safety of ProstateEZE Max, an orally dosed herbal preparation containing Cucurbita pepo, Epilobium parviflorum, lycopene, Pygeum africanum and Serenoa repens in the management of symptoms of medically diagnosed benign pro...
    Buy PDF